Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 10/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.39 |
| ▸ | SENP1 | Q9P0U3 | 3/20 | 0.39 |
| ▸ | SENP5 | Q96HI0 | 2/20 | 0.39 |
| ▸ | SENP2 | Q9HC62 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14613333 | 0.90 | EPHB4 (0.45) | KDR | |
| SCHEMBL14051031 | 0.88 | KCNK3 (0.42) | GSK3BRETKDRCDK2CCNE1 | |
| SCHEMBL14613477 | 0.88 | KCNK3 (0.42) | GSK3BRETKDRCDK2CCNE1 | |
| SCHEMBL14581256 | 0.87 | AURKA (0.45) | GSK3BRETKDRCDK2CCNE1 | |
| SCHEMBL14613329 | 0.87 | NFATC1 (0.50) | GSK3BCDK2CCNE1SIRT2SIRT1 | |
| SCHEMBL14051030 | 0.87 | MAPT (0.42) | GSK3BCDK2SENP1SENP5SENP2 | |
| SCHEMBL14418833 | 0.86 | KISS1R (0.46) | GSK3BSENP1SENP5SENP2MEN1 | |
| SCHEMBL14581408 | 0.85 | SENP1 (0.50) | GSK3BCDK2SENP1SENP5SENP2 | |
| SCHEMBL13288878 | 0.85 | CDK2 (0.49) | GSK3BCDK2SENP1SENP5SENP2 | |
| SCHEMBL14613272 | 0.85 | GSK3B (0.42) | GSK3BRETKDRCDK2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | CDK2, CDK5, CDKN1A | GSK3B 937/4885RET 2240/4885KDR 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.